



CLAIMS


1. A compound selected from the group consisting of



Dimer 13;




Dimer 18;




Dimer 19;


5




Dimer 20;




Dimer 24;




Dimer 28;




Dimer 32;




Dimer 54;




Dimer 55;




Dimer 56;



Dimer 58;



Dimer 65; or



Dimer 83;

wherein the disulfide linkages between the Cys₆ and Cys₁₁ residues of the A-chain polypeptide and the disulfide linkages between the Cys₇ and Cys₂₀ of the A-chain to the Cys₇ and Cys₁₉ of the B-chain polypeptide, respectively, are represented by the solid line therebetween; wherein the linking moieties are covalently linked to the epsilon amino acid of the shown lysine residue, wherein the A-chain polypeptide for **Dimers 13, 18, 19, 20, 24, 28, 32, 54, 55, 56, 58, 65 and 83** has the amino acid sequence shown in SEQ ID NO:1; the B-chain polypeptide for **Dimers 13, 24, 54, 55, 56 and 58** has the amino acid sequence shown in SEQ ID NO:2; the B-chain polypeptide for **Dimers 18 and 32** has the amino acid sequence

shown in SEQ ID NO:6; the B-chain polypeptide for **Dimers 19, 65 and 83** has the amino acid sequence shown in SEQ ID NO:9; the B-chain polypeptide for **Dimers 20 and 28** has the amino acid sequence shown in SEQ ID NO:10.

5 2. A composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier.

 3. A composition for use in the treatment of diabetes comprising a compound of claim 1.

10


 4. The composition of claim 3, wherein the diabetes is Type 1 diabetes, Type 2 diabetes, or gestational diabetes.

15 5. Use of a compound of claim 1 in the manufacture of a medicament for the treatment of diabetes.

 6. The use of claim 5, wherein the diabetes is Type 1 diabetes, Type 2 diabetes, or gestational diabetes.

20

7. A compound having the formula



Dimer 24;

wherein the disulfide linkages between the Cys6 and Cys11 residues of the A-chain polypeptide and the disulfide linkages between the Cys7 and Cys20 of the A-chain to the Cys7 and Cys19 of the B-chain polypeptide, respectively, are represented by the solid line therebetween; wherein the linking moieties are covalently linked to the epsilon amino acid of the shown lysine residue, wherein the A-chain polypeptide has the amino acid sequence shown in SEQ ID NO:1 and the B-chain polypeptide has the amino acid sequence shown in SEQ ID NO: 2.

8. A composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.

9. A composition for use in the treatment of diabetes comprising a compound of claim 7.

10. The composition of claim 9, wherein the diabetes is Type 1 diabetes, Type 2 diabetes, or gestational diabetes.

11. Use of a compound of claim 7 in the manufacture of a medicament for the treatment of diabetes.

12. The use of claim 11, wherein the diabetes is Type 1 diabetes, Type 2 diabetes, or gestational diabetes.